​FDA Approvals

Sign up to get the latest information on cancer research and AACR events!

*By clicking Sign Up Now you agree to our terms and read our privacy policy.

 

 

New PARP Inhibitor Approved for Breast Cancer1321The FDA approval of talazoparib means there are now two PARP inhibitors that can be used to treat patients with breast cancer who have an inherited BRCA mutation.11/20/2018 5:33:13 PM300https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1810031N_FDAapp_Talazoparib_Thumb_150x190_1.jpg" style="BORDER&#58;0px solid;" />New PARP Inhibitor Approved for Breast CancerThe FDA approval of talazoparib means there are now two PARP inhibitors that can be used to treat patients with breast cancer who have an inherited BRCA mutation.82
New Immunotherapeutic Approved for Common Skin Cancer949The FDA decision makes cemiplimab-rwlc the first-ever treatment approved specifically for treating squamous cell carcinoma.11/20/2018 5:33:24 PM190https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1810031M_FDAapp_Immuno_SquamousCell_Thumb_150x190_1.jpg" style="BORDER&#58;0px solid;" />New Immunotherapeutic Approved for Common Skin CancerThe FDA decision makes cemiplimab-rwlc the first-ever treatment approved specifically for treating squamous cell carcinoma.79
A New Targeted Therapy Option for Lung Cancer1327The FDA adds a fifth molecularly targeted therapeutic option for the treatment of lung cancer driven by EGFR mutations.11/20/2018 5:33:33 PM128https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1810031K_FDAapp_LungCancer_Thumb_150x190_1.jpg" style="BORDER&#58;0px solid;" />A New Targeted Therapy Option for Lung CancerThe FDA adds a fifth molecularly targeted therapeutic option for the treatment of lung cancer driven by EGFR mutations.81
Targeting Several Blood Cancers669The FDA has approved a new molecularly targeted therapeutic called duvelisib for treating certain patients with blood cancer.11/20/2018 5:33:43 PM50https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1810031L_FDAapp_BloodCancer_Thumb_150x190_1.jpg" style="BORDER&#58;0px solid;" />Targeting Several Blood CancersThe FDA has approved a new molecularly targeted therapeutic called duvelisib for treating certain patients with blood cancer.80
A New Type of Targeted Therapy for Leukemia163The FDA has approved the first of a new type of molecularly targeted therapy for use in treating certain patients with a rare type of leukemia.11/20/2018 5:33:53 PM98https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1810031H_FDAapp_Leukemia_Thumb_150x190_1.jpg" style="BORDER&#58;0px solid;" />A New Type of Targeted Therapy for LeukemiaThe FDA has approved the first of a new type of molecularly targeted therapy for use in treating certain patients with a rare type of leukemia.77
Combining Targeted Therapy and Immunotherapy for Non-Hodgkin Lymphoma6266The FDA has approved the combination of ibrutinib and rituximab as a new treatment for a rare form of non-Hodgkin lymphoma.11/20/2018 5:34:01 PM125https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1810031J_FDAapp_Walden_Thumb_150x190_1.jpg" style="BORDER&#58;0px solid;" />Combining Targeted Therapy and Immunotherapy for Non-Hodgkin LymphomaThe FDA has approved the combination of ibrutinib and rituximab as a new treatment for a rare form of non-Hodgkin lymphoma.75
Increasing Liver Cancer Treatment Options1637The FDA has approved expanding the use of lenvatinib to treat certain patients with the most common type of liver cancer.11/20/2018 5:34:11 PM98https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1810031I_FDAapp_LiverCancer_Thumb_150x190_1.jpg" style="BORDER&#58;0px solid;" />Increasing Liver Cancer Treatment OptionsThe FDA has approved expanding the use of lenvatinib to treat certain patients with the most common type of liver cancer.76
Expanding Immunotherapy to Small Cell Lung Cancer790The FDA has expanded the use of the immunotherapeutic nivolumab to treat certain patients with small cell lung cancer.11/20/2018 5:34:21 PM33https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1810031G_FDAapp_Immuno_SmallCell_Thumb_150x190_1.jpg" style="BORDER&#58;0px solid;" />Expanding Immunotherapy to Small Cell Lung CancerThe FDA has expanded the use of the immunotherapeutic nivolumab to treat certain patients with small cell lung cancer.78
First Immunotherapeutic for Rare Types of Non-Hodgkin Lymphoma2773The FDA has approved a new immunotherapeutic for treating two types of cutaneous T-cell lymphoma, mycosis fungoides and Sézary syndrome.11/20/2018 5:34:31 PM83https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1810031C_FDAapp_NHL_Thumb_150x190_1.jpg" style="BORDER&#58;0px solid;" />First Immunotherapeutic for Rare Types of Non-Hodgkin LymphomaThe FDA has approved a new immunotherapeutic for treating two types of cutaneous T-cell lymphoma, mycosis fungoides and Sézary syndrome.73
Targeting Radiotherapy to Treat Rare Neuroendocrine Tumors3425The FDA has approved a new targeted radiotherapeutic for treating two rare neuroendocrine tumors, pheochromocytomas and paragangliomas.11/20/2018 5:34:41 PM32https://www.aacrfoundation.org/approvals/Pages/Forms/AllItems.aspxhtmlFalseaspx<img alt="" src="/PublishingImages/FDA%20approvals/1810031A_FDAapp_NETs_Thumb_150x190_1.jpg" style="BORDER&#58;0px solid;" />Targeting Radiotherapy to Treat Rare Neuroendocrine TumorsThe FDA has approved a new targeted radiotherapeutic for treating two rare neuroendocrine tumors, pheochromocytomas and paragangliomas.74

The American Association for Cancer Research (AACR) is a 501c3 registered nonprofit organization with offices at 615 Chestnut Street, 17th Floor, Philadelphia, PA 19106 | 215.440.9300